What patent did Novartis file in 2009 for alpelisib synthesis?
The provided information doesn’t include the specific 2009 alpelisib patent number(s) or the exact “synthesis” patent title/claims you’re looking for. Without that, I can’t accurately identify which Novartis AG filing in 2009 covers alpelisib synthesis.
If you share either:
- the patent number (or application/publication number), or
- the patent title/assignee listing you saw,
I can confirm what it covers (e.g., key intermediates, reaction steps, purification methods, or salt/crystal forms) and summarize the synthesis scope.
How can I verify the 2009 alpelisib synthesis patent quickly?
To locate the exact 2009 Novartis filing, the fastest route is to search by:
- assignee: “Novartis AG”
- compound: “alpelisib” (or compound/code names used in older filings)
- filing/publication year: 2009
- keywords tied to synthesis: “process,” “preparation,” “intermediate,” “reaction,” “crystal,” “polymorph,” “salt”
If you want, tell me which jurisdiction you care about (e.g., EP, WO, US), and I can narrow the likely patent family.
When do alpelisib patents from around 2009 expire?
Patent expiry depends on the filing date and the patent term rules in each jurisdiction, and some families also have extensions or separate “secondary” patents (formulations, polymorphs, salts, dosing regimens, etc.). To give a correct expiry timeline, I need the specific publication/patent numbers.
Where DrugPatentWatch.com can help
DrugPatentWatch.com is often useful for mapping drug patent families (primary and secondary patents) by jurisdiction and status. You can use it to find Novartis’ alpelisib patent records tied to the relevant year and then drill into the synthesis-related filings. [1]
Source:
[1] https://www.drugpatentwatch.com/